ATOS RSI Chart
Last 7 days
5.4%
Last 30 days
16.3%
Last 90 days
55.5%
Trailing 12 Months
120.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2015 | 0 | 0 | 0 | 0 |
2014 | 474.0K | 157.8K | 84.6K | 0 |
2013 | 609.8K | 712.8K | 683.8K | 632.6K |
2012 | 0 | 0 | 0 | 481.8K |
2011 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 10, 2024 | finn jonathan | bought | 44,250 | 1.77 | 25,000 | - |
Nov 15, 2023 | weaver gregory l | sold | -32,500 | 0.65 | -50,000 | former evp, cfo, & director |
Jun 20, 2023 | weaver gregory l | bought | 48,500 | 0.97 | 50,000 | evp & cfo |
Jul 02, 2021 | weaver gregory l | acquired | 365,337 | 2.2198 | 164,581 | - |
Jul 02, 2021 | weaver gregory l | sold | -599,833 | 5.58 | -107,497 | - |
Jul 02, 2021 | weaver gregory l | sold (taxes) | -365,338 | 6.4 | -57,084 | - |
Which funds bought or sold ATOS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 70,295 | 70,295 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 2,040 | 1,779,550 | 1,821,140 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -79.42 | -82,191 | 59,771 | -% |
May 15, 2024 | Mariner, LLC | unchanged | - | 97,437 | 190,638 | -% |
May 15, 2024 | Laurion Capital Management LP | unchanged | - | 2,047,740 | 4,006,440 | 0.03% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 62,242 | 62,242 | -% |
May 15, 2024 | TWO SIGMA ADVISERS, LP | reduced | -26.59 | 11,124 | 33,300 | -% |
May 15, 2024 | Brevan Howard Capital Management LP | new | - | 24,599 | 24,599 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -99.99 | -9,457 | 2.00 | -% |
May 15, 2024 | Cetera Advisors LLC | new | - | 71,816 | 71,816 | -% |
Unveiling Atossa Genetics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Atossa Genetics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Atossa Genetics Inc News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q3 | 2014Q2 | 2014Q1 | 2013Q4 | 2013Q3 | 2013Q2 | 2013Q1 | 2012Q4 | 2012Q3 | 2012Q2 | 2012Q1 | 2011Q4 |
Revenue | -100.0% | - | 772,244 | 2,694,157 | 1,873,268 | 938,347 | 3,426 | 9,875 | 24,124 | 47,213 | 76,597 | 326,078 | 182,670 | 98,456 | 105,576 | 223,097 | 54,713 | - |
Cost Of Revenue | -646.4% | -1,712,327 | 313,406 | - | - | - | - | - | - | 30,957 | 25,938 | 222,160 | 66,464 | 5,760 | 9,000 | 17,788 | 3,197 | - |
Gross Profit | -392.4% | -1,341,871 | 458,838 | - | - | 2,713 | 3,426 | 9,875 | 24,124 | -133,690 | 50,659 | 103,918 | 116,206 | 92,696 | 90,499 | 205,309 | 27,709 | - |
Interest Expenses | - | - | - | - | 1,784 | 13,426 | 151 | 1,443 | 749 | - | 1.00 | 352 | 7.00 | 224 | 7,756 | 2,446 | 1,613 | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -5.4% | 91.00 | 96.00 | 102 | 108 | 116 | 124 | 127 | 134 | 137 | 141 | 143 | 146 | 141 | 43.00 | 11.00 | 10.00 | 12.00 | 14.00 | 17.00 | 19.00 | 21.00 |
Current Assets | -5.6% | 87.00 | 92.00 | 98.00 | 106 | 111 | 118 | 123 | 133 | 137 | 141 | 143 | 146 | 141 | 43.00 | 11.00 | 10.00 | 12.00 | 14.00 | 16.00 | 18.00 | 21.00 |
Cash Equivalents | -5.0% | 84.00 | 88.00 | 94.00 | 99.00 | 104 | 111 | 117 | 126 | 131 | 136 | 140 | 142 | 138 | 40.00 | 9.00 | 7.00 | 9.00 | 13.00 | 15.00 | 17.00 | 20.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 1.8% | 5.00 | 5.00 | 3.00 | 3.00 | 3.00 | 6.00 | 3.00 | 4.00 | 2.00 | 3.00 | 2.00 | - | - | 16.00 | 2.00 | 2.00 | 1.00 | 1.00 | 2.00 | 1.00 | 2.00 |
Current Liabilities | 1.8% | 5.00 | 5.00 | 3.00 | 3.00 | 3.00 | 6.00 | 3.00 | 4.00 | 2.00 | 3.00 | 2.00 | 2.00 | 1.00 | 16.00 | 2.00 | 2.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 |
Shareholder's Equity | -5.8% | 86.00 | 91.00 | 98.00 | 105 | 113 | 118 | 124 | 130 | 135 | 138 | 141 | 144 | 140 | 27.00 | 10.00 | 8.00 | 11.00 | 13.00 | 15.00 | 18.00 | 19.00 |
Retained Earnings | -3.2% | -192 | -186 | -178 | -172 | -162 | -156 | -148 | -140 | -134 | -129 | -124 | -119 | -112 | -111 | -104 | -100 | -97.02 | -94.07 | -91.45 | -88.17 | -80.90 |
Additional Paid-In Capital | 0.2% | 257 | 256 | 255 | 254 | 252 | 251 | 249 | 248 | 246 | 244 | 242 | 240 | 229 | 130 | 112 | 107 | 106 | 105 | 104 | 103 | 98.00 |
Shares Outstanding | 0.2% | 126 | 125 | 125 | 127 | 127 | 127 | 127 | 127 | 127 | 127 | 114 | 107 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 160 | - | - | - | 138 | - | - | - | 796 | - | - | - | 35.00 | - | - | - | 23.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 15.0% | -4,698 | -5,530 | -3,883 | -4,465 | -7,022 | -4,523 | -5,410 | -5,949 | -4,878 | -3,665 | -3,062 | -5,337 | -4,408 | -3,432 | -2,678 | -2,229 | -3,229 | -2,708 | -1,768 | -2,502 | -2,148 |
Share Based Compensation | - | 417 | - | - | - | 1,573 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Investing | -Infinity% | -6.00 | - | -1.00 | -13.00 | - | -2,008 | -2,706 | - | -13.00 | - | -9.00 | - | - | 367* | -2.76 | - | - | - | - | - | - |
Cashflow From Financing | - | 204 | - | -1,475 | - | - | - | - | - | - | 1.00 | 679 | 10,196 | 102,428 | 33,880 | 4,324 | - | - | - | - | - | 11,337 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Consolidated Consolidated Statements of Operations (Current Period Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses | ||
Research and development | $ 3,748,000 | $ 3,508,000 |
General and administrative | 3,232,000 | 3,590,000 |
Total operating expenses | 6,980,000 | 7,098,000 |
Operating loss | (6,980,000) | (7,098,000) |
Interest income | 1,138,000 | 850,000 |
Other expense, net | (36,000) | (33,000) |
Loss before income taxes | (5,878,000) | (6,281,000) |
Income taxes benefit | 0 | 0 |
Net loss | $ (5,878,000) | $ (6,281,000) |
Net loss per share of common stock - basic (in dollars per share) | $ (0.05) | $ (0.05) |
Net loss per share of common stock - diluted (in dollars per share) | $ (0.05) | $ (0.05) |
Weighted average shares outstanding used to compute net loss per share- basic (in shares) | 125,319,778 | 126,624,110 |
Weighted average shares outstanding used to compute net loss per share - diluted (in shares) | 125,319,778 | 126,624,110 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 83,960 | $ 88,460 |
Restricted cash | 110 | 110 |
Prepaid materials | 1,372 | 1,487 |
Prepaid expenses and other current assets | 1,613 | 2,162 |
Total current assets | 87,055 | 92,219 |
Investment in equity securities | 1,710 | 1,710 |
Other assets | 2,322 | 2,323 |
Total Assets | 91,087 | 96,252 |
Current liabilities | ||
Accounts payable | 1,230 | 806 |
Accrued expenses | 1,613 | 973 |
Payroll liabilities | 659 | 1,654 |
Other current liabilities | 1,826 | 1,803 |
Total current liabilities | 5,328 | 5,236 |
Total Liabilities | 5,328 | 5,236 |
Commitments and contingencies (Note 13) | ||
Stockholders' equity | ||
Convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock - $0.18 par value; 175,000,000 shares authorized; 125,507,814 and 125,304,064 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 22,829 | 22,792 |
Additional paid-in capital | 256,571 | 255,987 |
Treasury stock, at cost; 1,320,046 shares of common stock at March 31, 2024 and December 31, 2023 | (1,475) | (1,475) |
Accumulated deficit | (192,166) | (186,288) |
Total Stockholders' Equity | 85,759 | 91,016 |
Total Liabilities and Stockholders' Equity | $ 91,087 | $ 96,252 |